HF
PMCB icon

HRT Financial’s PharmaCyte Biotech PMCB Stock Holding History

HRT Financial’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Sell
15,451
-9,290
-38% -$6.99K ﹤0.01% 3981
2026
Q1 		$16K Sell
24,741
-158,060
-86% -$121K ﹤0.01% 3593
2025
Q4 		$132K Buy
+182,801
New +$165K ﹤0.01% 2735

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial's PMCB Position: Q2 2026 in Review

HRT Financial reduced its PharmaCyte Biotech (PMCB) stake by 38% in Q2 2026, selling an estimated $6.99K and leaving 15,451 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #3981.

HRT Financial first reported a position in PMCB in Q4 2025 and has held it in 3 quarters since. The position peaked at $132K in Q4 2025. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • HRT Financial held 15,451 shares of PharmaCyte Biotech worth $11K as of Q2 2026.
  • HRT Financial sold 9,290 PharmaCyte Biotech shares in Q2 2026, an estimated $6.99K.
  • PharmaCyte Biotech made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3981 holding.
  • HRT Financial first reported a position in PharmaCyte Biotech in Q4 2025 and has held it in 3 quarters since.
  • HRT Financial's PharmaCyte Biotech position peaked at $132K in Q4 2025.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.